Skip to main content
. Author manuscript; available in PMC: 2023 Jun 14.
Published in final edited form as: Eur Urol. 2016 Jul 21;71(5):766–773. doi: 10.1016/j.eururo.2016.06.046

Table 4 –

Multivariate Cox regression of clinical outcomes by subgroups.

Clinical outcome HR 95% CI p value
Biochemical recurrencea
 Total RT dose 0.95 (0.91, 0.98) 0.0043
 ADT duration 1.00 (0.99, 1.01) 0.48
Distant metastasis
 Total RT dose 0.91 (0.87, 0.96) 0.0001
 ADT duration 1.01 (1, 1.02) 0.26
 Salvage RT 0.47 (0.19, 1.15) 0.099
 Adjuvant RT 0.86 (0.2, 3.72) 0.84
Prostate cancer specific mortality
 Total RT dose 0.93 (0.87, 0.99) 0.020
 ADT duration 1.01 (1, 1.02) 0.051
 Salvage RT 0.53 (0.19, 1.5) 0.23
 Adjuvant RT 0.55 (0.07, 4.23) 0.57
Overall survival
 Total RT dose 0.98 (0.95, 1.01) 0.23
 ADT duration 1.00 (0.99, 1.01) 0.53
 Salvage RT 0.47 (0.19, 1.15) 0.099
 Adjuvant RT 0.86 (0.2, 3.72) 0.84

ADT = androgen deprivation therapy; CI = confidence interval; HR = hazard ratio; RT = radiotherapy.

a

The multivariate Cox regression model derived-hazard ratios are adjusted for age, Gleason score, clinical T-stage, and initial prostate-specific antigen, year of treatment, local salvage (with time to salvage as a covariate), and systemic salvage (with time to salvage as a covariate) and refer to outcomes through 10 yr of follow-up. Hazard ratios <1 suggest the outcome (eg, distant metastasis) has a lower hazard of occurring with higher values of continuous variables (total radiotherapy dose or androgen deprivation therapy duration) or “yes” for binary variables (salvage radiotherapy or adjuvant radiotherapy).